Skip to Content

Join the 'Plague Prophylaxis' group to help and get support from people like you.

Plague Prophylaxis News

Avelox Approved for Plague

Posted 10 May 2015 by Drugs.com

FRIDAY, May 8, 2015 – Avelox (moxifloxacin) was approved by the U.S. Food and Drug Administration on Friday to treat plague, a rare but deadly bacterial infection that can strike the lungs (pneumonic), blood (septicemic) or lymph nodes (bubonic). Only 1,000 to 2,000 cases are reported worldwide annually, the agency said in a news release. It's spread by the bites of infected fleas, or by contact with infected animals or people. However, the Yersinia pestis bacterium could be released intentionally as a bioterrorism agent. Avelox was approved under rules that allow findings from well-controlled animal studies (in this case, African green monkeys) in instances when it isn't ethical or feasible to conduct trials among humans. The disease is so rare that it wouldn't be possible to conduct adequate trials involving people, the FDA said. Avelox's label carries a boxed warning of the ... Read more

Related support groups: Avelox, Moxifloxacin, Avelox IV, Plague Prophylaxis, Plague

FDA Approves Avelox (moxifloxacin) as Additional Antibacterial Treatment for Plague

Posted 8 May 2015 by Drugs.com

May 8, 2015 - The U.S. Food and Drug Administration today approved Avelox (moxifloxacin) to treat patients with plague, a rare and potentially fatal bacterial infection. The agency approval for plague includes use of the drug for the treatment of pneumonic plague (infection of the lungs), and septicemic plague (infection of the blood). Avelox is also approved for prevention of plague in adult patients. Plague is extremely rare in most parts of the world, including the United States, with 1,000 to 2,000 cases worldwide each year. The three most common forms of plague are bubonic plague (infection of the lymph nodes), pneumonic plague and septicemic plague. “Today’s approval provides an additional therapy for the treatment of plague,” said Edward Cox, M.D., M.P.H, director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research. Plague can be spread ... Read more

Related support groups: Avelox, Moxifloxacin, Avelox IV, Plague Prophylaxis, Plague

FDA Approves Levaquin as an Antibacterial Treatment for Plague

Posted 30 Apr 2012 by Drugs.com

April 27, 2012 – The U.S. Food and Drug Administration today approved Levaquin (levofloxacin) to treat patients with plague, a rare and potentially deadly bacterial infection. The agency also approved the drug to reduce the risk of getting plague after exposure to Yersinia pestis, the bacterium that causes the disease. Plague is extremely rare in most parts of the world, including the United States, with 1,000 to 2,000 cases worldwide each year. The three most common forms of plague are bubonic plague (infection of the lymph nodes), pneumonic plague (infection of the lungs), and septicemic plague (infection of the blood). Primarily an animal disease, plague can be spread to humans through bites from infected fleas, contact with infected animals or humans, or laboratory exposure. Yersinia pestis also is considered a biological threat agent, which could potentially be used as a ... Read more

Related support groups: Levaquin, Levofloxacin, Plague, Plague Prophylaxis

Levaquin Approved to Treat or Prevent Plague

Posted 27 Apr 2012 by Drugs.com

FRIDAY, April 27 – Approval of the antibiotic Levaquin (levofloxacin) has been expanded by the U.S. Food and Drug Administration to include plague, a rare but deadly bacterial infection. The disease is extremely rare in the United States, and only about 1,000 to 2,000 cases occur each year across the globe, the agency said in a news release. The three most common forms of plague include bubonic (affecting the lymph nodes), pneumonic (lungs) and septicemic (blood stream). Animals are most frequently infected, although plague can be spread to people by fleas, contact with infected animals or other people, or by exposure in the laboratory. The bacterium that causes plague, Yersinia pestis, is considered a potential bioterrorism agent, the FDA said. Levaquin was tested under the agency's Animal Efficacy Rule, which allows findings from carefully controlled tests in animals to be applied to ... Read more

Related support groups: Levaquin, Levofloxacin, Levaquin Leva-Pak, Plague Prophylaxis, Plague

Ask a Question

Further Information

Related Drug Support Groups

Levaquin, levofloxacin, Avelox, moxifloxacin, Avelox IV, plague vaccine, Levaquin Leva-Pak